Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,910 result(s) found. Displaying page 64 of 146.
    «« First « Previous 60  61  62  63  64  65  66  67  68  Next» Last»»
    EudraCT Number: 2017-000953-38 Sponsor Protocol Number: MK-1986-014 Start Date*: 2018-02-07
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 1, Single-and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old
    Medical condition: Treatment or prophylaxis against Gram-positive infections
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) GB (GB - no longer in EU/EEA) NO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000309-64 Sponsor Protocol Number: AL-ACC-01 Start Date*: 2019-10-24
    Sponsor Name:Ayala Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
    Medical condition: Adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005659-15 Sponsor Protocol Number: ACE-011-B-THAL-001 Start Date*: 2012-10-04
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)- thalassemia
    Medical condition: Subjects with red blood cell (RBC) transfusion dependent β-thalassemia major and β thalassemia intermedia, as well as non-transfusion dependent β-thalassemia intermedia will take part in this study.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062923 Thalassemia intermedia LLT
    20.1 100000004850 10054661 Thalassemia major LLT
    20.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003149-41 Sponsor Protocol Number: IgPro20_2001 Start Date*: 2019-07-16
    Sponsor Name:CSL Behring GmbH
    Full Title: A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglob...
    Medical condition: Safety and Pharmacokinetics in subjects with diffuse cutaneous systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005035-33 Sponsor Protocol Number: R2477-FOP-1623 Start Date*: 2017-08-15
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progres...
    Medical condition: Fibrodysplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004705-26 Sponsor Protocol Number: LPS15497 Start Date*: 2020-03-24
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: A randomized double blind placebo controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000337-39 Sponsor Protocol Number: 4658-102-OLE Start Date*: Information not available in EudraCT
    Sponsor Name:Sarepta Therapeutics, Inc
    Full Title: An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients with Duchenne Muscular Dystrophy Who Have Completed Study 4658-102
    Medical condition: Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: FR (Ongoing) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002153-11 Sponsor Protocol Number: GS-LHON-CLIN-06 Start Date*: 2018-02-12
    Sponsor Name:GENSIGHT BIOLOGICS
    Full Title: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10062951 Leber's hereditary optic atrophy neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003162-25 Sponsor Protocol Number: MEA116841 Start Date*: 2015-02-26
    Sponsor Name:GlaxoSmithKline Research Ltd
    Full Title: Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in...
    Medical condition: Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10018701 Granulomatous disease LLT
    21.1 100000004866 10072580 Granulomatous polyangiitis LLT
    21.0 100000004864 10014956 Eosinophilic granuloma LLT
    20.1 100000004870 10014957 Eosinophilic granulomatous vasculitis LLT
    21.1 100000004866 10056218 Necrotising granulomatous vasculitis LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004866 10036023 Polyangiitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001526-59 Sponsor Protocol Number: CL2-95011-001 Start Date*: 2020-10-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study
    Medical condition: Primary Sjögren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004768-69 Sponsor Protocol Number: INCB54828-207 Start Date*: 2019-10-16
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectabl...
    Medical condition: Male and female participants at least 18 years of age who have a solid tumor malignancy with an activating FGFR mutation or fusion/rearrangement who have progressed on prior therapies and have no a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003391-13 Sponsor Protocol Number: D3250C00059 Start Date*: 2019-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asth...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000139-28 Sponsor Protocol Number: IO102-012 Start Date*: 2018-08-20
    Sponsor Name:IO Biotech Aps
    Full Title: An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients wit...
    Medical condition: Metastatic Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002552-27 Sponsor Protocol Number: B9991004 Start Date*: 2016-07-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WI...
    Medical condition: Locally advanced or metastatic solid tumors [eg, non-small cell lung cancer (NSCLC), melanoma, and squamous cell carcinoma of the head and neck (SCCHN)] triple-negative breast cancer (TNBC), or col...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001379-21 Sponsor Protocol Number: VX15-770-126 Start Date*: 2017-08-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Init...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000669-21 Sponsor Protocol Number: 1218-0091 Start Date*: 2018-04-02
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
    Full Title: A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ...
    Medical condition: Diabetes Mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) Outside EU/EEA DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-023988-17 Sponsor Protocol Number: 260777 Start Date*: 2014-04-04
    Sponsor Name:BrepCo Biopharma Limited
    Full Title: Management of Hypotension In the Preterm: A multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age newborn
    Medical condition: Low Blood Pressure
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10024895 Low blood pressure LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002073-56 Sponsor Protocol Number: Aramchol-018 Start Date*: 2020-01-06
    Sponsor Name:Galmed Research and Development, Ltd.
    Full Title: A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMO...
    Medical condition: Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000826-31 Sponsor Protocol Number: NN7999-3774 Start Date*: 2012-08-24
    Sponsor Name:Novo Nordisk
    Full Title: Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B
    Medical condition: Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006458-91 Sponsor Protocol Number: KU36-44 Start Date*: 2007-05-22
    Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies)
    Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat...
    Medical condition: Advanced breast cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Ongoing) DE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 60  61  62  63  64  65  66  67  68  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 12:25:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA